الرئيسية » أرشيف الكاتب: Catherine Skari (صفحة 5)

أرشيف الكاتب: Catherine Skari

Gene Therapy and Thalassaemia: The Patients’ Perspective survey!

  A significant number of gene therapy approaches are currently undergoing clinical trials, some of which are already producing encouraging results. The Bluebird Bio’s gene therapy product, under the name ZYNTEGLO™, has received positive comments from the scientific committees of the European drug regulatory authority (EMA). This means that the practical ...

أكمل القراءة »

Delegation visit to Austria – 11-13 April 2019

  TIF’s Board of Directors Member and Expert Patient, Mr. George Constantinou, and TIF’s collaborators Dr. phil Eva-Maria Knoll and Dr. Anne Yardumian, were delegated to visit Austria on 11-13 April, 2019, a country of special focus for the THALIA project, due to the fact that it has become a ...

أكمل القراءة »

Living with Transfusion-Dependent β-Thalassaemia (TDT)

In its most severe form and without adequate care, thalassaemia can be lethal in early childhood, and although  International Thalassaemia Day has come and gone, awareness is paramount.   Andrew Obenshain, Head of Europe at gene therapy company bluebird bio, looks into what it means to live with thalassaemia, with ...

أكمل القراءة »